Sir Greg Winter, of the University of Cambridge, has been jointly awarded the 2018 Nobel Prize in Chemistry, along with Frances Arnold and George Smith, for his pioneering work in using phage display for the directed evolution of antibodies, with the aim of producing new pharmaceuticals.
Researchers at the University of Cambridge have designed antibodies that target the protein deposits in the brain associated with Alzheimer’s disease, and stop their production.
The path from innovation to impact can be long and complex. Here we describe the 30-year journey behind the development of a drug now being used to treat multiple sclerosis.
Cambridge neurologists have shown that an antibody used to treat leukaemia also limits and repairs the damage in multiple sclerosis.
© 2025 University of Cambridge